SolEmuls® Technology: A Way to Overcome the Drawback of Parenteral Administration of Insoluble Drugs

In this article, a nanosuspension of AmB was prepared and mixed with the preformed parenteral emulsion Lipofundin® and subjected to high-pressure homogenization (SolEmuls® technology). Characterization was performed by photon correlation spectroscopy (PCS), laser diffractometry (LD), and zeta potential measurements. Drug incorporation was studied by using light microscopy. The produced emulsions were further investigated by comparing them with the commercially available Fungizone® in regard to antifungal efficiency and toxicity. Results suggest that through the SolEmuls® process the AmB forms a reservoir, out of which it is released in such a manner that it is more efficient and less toxic than Fungizone®.